Home Blog Page 1146

Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

SYDNEY, Dec. 24, 2025 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent’s Hospital Sydney, for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026, Europe’s biggest urological conference, to be held 13-16 March 2026 in London, UK[2].

Co-PSMA’s official study title is “Comparative performance of 64Copper [64Cu]-SAR-bisPSMA vs. 68Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in the setting of biochemical failure following radical prostatectomy”. This Phase II IIT evaluated the performance of Clarity’s diagnostic product, 64Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care (SOC) 68Ga-PSMA-11 in 50 patients with low prostate-specific antigen (PSA) who were candidates for curative salvage therapy. Eligible patients were required to have had radical prostatectomy with no salvage therapy and a PSA level between 0.2 and 0.75 ng/mL.

The results to be presented by Prof Emmett at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint, demonstrating that 64Cu-SAR-bisPSMA positron emission tomography (PET) / computed tomography (CT) detected significantly more lesions per patient than the SOC, 68Ga-PSMA-11 PET/CT[3]. These results further build on the growing body of evidence showing that 64Cu-SAR-bisPSMA improves the detection of prostate cancer, compared to the current SOC prostate-specific membrane antigen (PSMA) PET agents which are known to have low sensitivity, especially in patients with low PSA levels[4],[5].

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “64Cu-SAR-bisPSMA has been purposely developed at the benchtop to overcome the many shortfalls of the current SOC PSMA imaging agents. With the molecule only being invented some 7 years ago, we have already demonstrated at the cellular level, in animal models and now in multiple clinical trials, that 64Cu-SAR-bisPSMA is clearly differentiated from the competitors. In a very short amount of time, we have moved from invention to two registrational Phase III trials, both to complete recruitment next year, continuing to build on strong evidence generated to date of the improved diagnostic performance of our product through various clinical trials and real-world evidence (compassionate use supply). We reported earlier that our optimised agent detects more lesions in this IIT head-to-head comparison against the SOC product[3]. We also know that 64Cu-SAR-bisPSMA identifies more as well as smaller lesions and was able to do so earlier than SOC PSMA PET agents in our Phase II COBRA trial[6]. The full results from Co-PSMA will again reinforce the mounting data showing how 64Cu-SAR-bisPSMA can outperform SOC PSMA PET products.

“We are committed to a rigorous scientific and clinical development process, which has delivered exceptional results to date. The acceptance of the Co-PSMA data by this world-leading urology conference for an oral presentation is a testament to its strength and quality. This recognition not only highlights the impact of this research but also underscores the significant potential of 64Cu-SAR-bisPSMA to advance PSMA imaging and improve prostate cancer management. The abstract summary will be announced in mid-February, followed by the oral presentation in mid-March 2026.

“Prof Emmett is a global key opinion leader in the field of urologic nuclear medicine, with a strong track record of highly regarded scientific publications as well as extensive clinical experience. We are honoured to continue working together on our registrational AMPLIFY[7] and CLARIFY[8] trials and trust that her unique expertise and commitment to providing the best available patient care will help us to get closer to our mutual goal of improving detection and treatment paradigm for prostate cancer patients.

“With two US Food and Drug Administration (FDA) Fast Track Designations for 64Cu-SAR-bisPSMA and two ongoing registrational trials, we are extremely excited to enter the USD 2 billion PSMA PET imaging market as it is further expected to grow to over USD 3 billion by 2029 with not only a clearly differentiated agent, but also a product with substantial logistical benefits over the current competitors.”

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

Disclaimer

64Cu-SAR-bisPSMA is an unregistered product. The safety and efficacy of 64Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[9]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease[10].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor                                     

Lisa Sadetskaya

Executive Chairperson                                   

Director, Corporate Communications

ataylor@claritypharm.com 

lisa@claritypharm.com 

 

References

[1]  Clinicaltrials.gov Identifier: NCT06907641. https://clinicaltrials.gov/study/NCT06907641

[2]  EAU26. The Congress. https://eaucongress-new.uroweb.org/the-congress

[3]  Clarity Pharmaceuticals. Co-PSMA trial achieves primary endpoint. https://www.claritypharmaceuticals.com/news/co-psma-endpoint/.

[4]  Fendler WP et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096. PMID: 30920593; PMCID: PMC6567829.

[5]  Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin F, Adler S, Eclarinal P, McKinney YL, Citrin D, Dahut W, Wood BJ, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy. J Nucl Med. 2020 Jun;61(6):881-889. doi: 10.2967/jnumed.119.234799. Epub 2019 Nov 1. PMID: 31676732; PMCID: PMC9374042.

[6]  Nordquist et al. COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy. EANM 2024.

[7]  Clinicaltrials.gov Identifier: NCT06970847. https://clinicaltrials.gov/study/NCT06970847

[8]  Clinicaltrials.gov Identifier: NCT06056830. https://clinicaltrials.gov/study/ NCT06056830

[9]  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660

[10]  American Cancer Society: Key Statistics for Prostate Cancer. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

This announcement has been authorised for release by the Executive Chairperson.

NCAP 2026 Countdown: Raytron’s Thermal Camera Boosts Nighttime AEB and VRU Detection for OEMs

YANTAI, China, Dec. 24, 2025 /PRNewswire/ — As Euro NCAP prepares to roll out its 2026 safety protocol, the automotive industry is facing a fundamental shift, from post-crash protection to pre-collision avoidance. The new requirements introduce complex test scenarios, pushing vehicle perception systems to perform reliably under extreme conditions. Leveraging automotive-grade infrared thermal imaging, Raytron provides OEMs with a robust sensing foundation to address these challenges, enabling next-generation Advanced Driver Assistance Systems (ADAS) and Automatic Emergency Braking (AEB) systems to maintain safety performance even when visibility fails.

Why Thermal Imaging Matters for Euro NCAP 2026

Facing new Euro NCAP requirements, vehicle mounted thermal cameras leverage their physics-based infrared thermal imaging to complement perception gaps where traditional sensors fail. Independent of ambient light, they detect objects’ emitted heat, providing a distinct information dimension.

  • Overcome low-light/night challenges: Whether test fields meet 2000 lux or simulate night, thermal imagers clearly detect heat-emitting targets like pedestrians and cyclists, supporting ADAS under Euro NCAP.
  • Eliminate glare blind spots: In tunnels or sunset glare conditions where cameras fail, infrared night vision cameras maintain reliable perception, ensuring continuous data for CCFtap/CCCscp at intersections and preventing sensor-induced system failures.
  • Enhance Biological Object Detection: Strong contrast between pedestrians or animals and background in thermal imaging cameras accelerates accurate detection in busy urban scenes.

Raytron’s Thermal Imaging Engineered for Automotive Excellence

Raytron’s strength lies in its fully integrated automotive thermal imaging capabilities, spanning infrared thermal cameras to perception algorithms, all compliant with AEC-Q100 Grade 2 standards. The company’s solutions are already in production, powering the thermal imaging AEB system on the Zeekr 9X and featured in models from BYD and Geely. To date, Raytron’s thermal imaging modules have been adopted in over 20 vehicle models through 15 automakers. “Euro NCAP 2026 tests the limits of perception,” said Whilson Li, Raytron’s automotive executive. “We believe true ‘zero-collision’ safety must see through the dark. Raytron’s thermal imaging is becoming the foundational layer for all-weather autonomy.”

As vehicle safety paradigms shifts, Raytron is dedicated to providing the foundational perception layer essential for achieving the vision of zero-collision mobility.

For Further Information

Raytron Marketing Department

E-mail: sales@raytrontek.com

Website: https://en.raytrontek.com

Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study

SHANGHAI, Dec. 24, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&D code: 9MW1911) to initiate a Phase IIa clinical study in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

As the first domestic anti-ST2 monoclonal antibody candidate to enter clinical trials, 9MW1911 binds to the ST2 receptor with high affinity to block the IL-33/ST2 signaling pathway. It has already completed a Phase IIa study (N=80) in patients with moderate-to-severe COPD in China.

Results showed that 9MW1911 was safe and well-tolerated across all dose groups compared to placebo (N=20), with a similar adverse event incidence (70% vs. 85%). Immunogenicity was negative in all subjects, and no new safety risk signals were identified. Regarding pharmacokinetics, drug exposure increased as doses escalated. An exposure-response model can be preliminary established to define the dose-effect relationship, providing a basis for subsequent dose selection.

Pharmacokinetic results suggested that drug exposure increased with escalating doses. An exposure-response model can be preliminary established to define the dose-effect relationship, providing a basis for subsequent dose selection.

Efficacy data revealed that the annualized exacerbation rate of COPD demonstrated a dose-dependent decrease in the treatment arms. At the recommended Phase IIb dose (RP2D, N=30), the annualized rate of moderate-to-severe COPD exacerbations was reduced by over 30% compared to the placebo group. Furthermore, the annualized rate of severe exacerbations at the RP2D was reduced by over 40%, and the proportion of patients experiencing severe exacerbations was significantly lower than the placebo group (13.3% vs. 35%).

The Phase IIb clinical trial evaluating 9MW1911 in a larger COPD population achieved its first patient dosing in July 2025, with an interim analysis planned after data from at least 120 patients are collected. Based on the evaluation of Phase II outcomes, the company expects to launch a Phase III clinical study by the end of 2026 to further observe the drug’s safety, efficacy, and immunogenicity.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

 

Eastern International Ltd. Entered into Contract for its First Photovoltaic Power Generation Construction Project With a Total Contract Price of RMB 42.5 Million (approximately US$ 6.04 million)

HANGZHOU, China, Dec. 24, 2025 /PRNewswire/ — Eastern International Ltd. (“Eastern International” or the “Company”) (NASDAQ: ELOG), a provider of domestic and cross-border professional logistic services including project logistic and general logistic for Company clients, today announced that its wholly-owned subsidiary, Guizhou Tianrun Zhicheng Construction Engineering Co., Ltd. (“Guizhou Tianrun”), has entered into a construction contract (the “Contract”) with Weifang Branch of CSCEC Southwest Architecture & Design Institute (Shandong) Design Consulting Co., Ltd. for its Hebei Laiyuan 300 MW Centralized Photovoltaic Power Generation Project.

Pursuant to the Contract, Guizhou Tianrun will act as a subcontractor and be responsible for the construction of Phase I – 50 MW (the “Project”) of the Centralized Photovoltaic Power Generation Project, with a total contract price of RMB 42.5 million (approximately US$ 6.04 million). Guizhou Tianrun will be responsible for the foundation works, photovoltaic mounting structure installation, photovoltaic module installation, module string wiring, installation and wiring of photovoltaic combiner boxes and supply of certain auxiliary materials. The Project is scheduled to commence for construction before December 31, 2025.

Mr. Lin Tan, Chief Operating Officer of Eastern International Ltd. commented, “The commencement of the construction of the Company’s first photovoltaic power generation project marks the substantive progress of our business expansion in the new energy sector. Through our professional engineering and construction team, the Company will continue to actively participate in large-scale clean energy projects and their constructions, to provide high-quality and on-time delivery and support the green transformation of regional energy structure. With this new development, we believe the Company has entered a broader stage of new business.”

About Eastern International Ltd. 

Eastern International Ltd. (NASDAQ: ELOG) is a holding company incorporated in the Cayman Islands. The Company, through Suzhou TC-Link Logistics Co., Ltd. (“Suzhou TC-Link”) and Hangzhou TC-Link Logistics Supply Chain Management Co., Ltd., both wholly owned subsidiaries of the Company, provide domestic and cross-border professional logistic services including project logistic and general logistic for Company clients. Suzhou TC-Link was established on January 9, 2006, in Jiangsu Province, China. Suzhou TC-Link has obtained the internationally recognized IS09001 certificate of high-quality service (2015 standard). Eastern International has 7 wholly owned subsidiaries and 5 warehouses/logistic centers and 3 branch offices in China which operating network covers key cities in mainland China, Hong Kong, Southeast Asia and Central Asia. For more information, please visit https://www.elogint.com

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the final prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Eastern International specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. 

Contacts: 

Eastern International Ltd.
Mr. Lin Tan
Tel: +86 0571-82356096
Email: ir@elogint.com

Bybit Marks Seventh Anniversary With Exclusive EU-Only ZEN.COM PRO Plan Reward

VIENNA, Dec. 24, 2025 /PRNewswire/ — Bybit EU, the European arm of Bybit and a MiCAR-licensed crypto-asset service provider headquartered in Vienna, is commemorating Bybit’s Seventh Anniversary with the launch of its EU-only #7UpBybit Birthday Blast, featuring a special reward in partnership with ZEN.COM. Eligible EU participants may redeem 150 days of complimentary access to the ZEN PRO plan, valued at €34.50, through activities available exclusively to users on the Bybit EU platform.

This reward is part of the Bybit EU Daily Treasure Hunt, which runs from Nov. 26, 2025, at 10 a.m. UTC to Jan. 5, 2026, at 10 a.m. UTC. Only Bybit EU users participating in the EU anniversary campaign are able to earn and redeem Bybit Points for this benefit.

How It Works

  • The reward may be redeemed once per eligible EU user.
  • Users must be opening a ZEN.COM account for the first time in order to activate the ZEN PRO plan.
  • After redeeming the reward with Bybit Points on the EU platform, users will receive a unique reward code from Bybit EU for use with their new ZEN.COM account.
  • If the reward is redeemed by someone who is not new to ZEN.COM, the reward will be unusable and Bybit Points will not be refunded.

Throughout the anniversary period, only users on the Bybit EU platform can participate in tasks that earn Bybit Points, including daily check-ins, account verification with first top-up, daily spot trading, and referral activities conducted within the EU ecosystem.

Points may be redeemed across EU-only anniversary features, including USDC airdrops, fee savers, and 100,000 scratch cards available on a first-come, first-served basis.

T&Cs apply. More information on the EU campaign is available here.

Bybit Marks Seventh Anniversary With Exclusive EU-Only ZEN.COM PRO Plan Reward
Bybit Marks Seventh Anniversary With Exclusive EU-Only ZEN.COM PRO Plan Reward

#BybitEU / #TheCryptoHub

About Bybit EU

Bybit EU GmbH is an Austrian company that serves customers across the entire European Economic Area (EEA*) – with the exception of Malta – via the platform Bybit.eu. Operated by Bybit EU GmbH, a licensed Crypto-Asset Service Provider (CASP) under the Markets in Crypto-Assets Regulation (MiCAR), Bybit EU delivers fully regulated services, including crypto custody, exchange, and rewards products and more,  in full compliance with European regulations for investor protection and market integrity.

Bybit EU GmbH is a licensed Crypto-Asset-Service Provider under the Markets in Crypto Assets Regulation (MiCAR), authorized to offer the following services to residents of the European Economic Area (except Malta):

  • providing custody and administration of crypto-assets on behalf of clients;
  • exchange of crypto-assets for funds;
  • exchange of crypto-assets for other crypto-assets;
  • placing of crypto-assets; and
  • providing transfer services for crypto-assets on behalf of clients.

Bybit EU GmbH is neither the operator of a trading platform for crypto-assets nor provides investment advice.

Media Contact: press@bybit.com
www.bybit.eu 

Disclaimer: This press release is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell digital assets. The products and services mentioned herein are subject to applicable laws and regulations in the relevant jurisdictions and may not be available in certain regions.

AMTD Digital’s Subsidiary TGE Successfully Executed Multiple SPAs for Hotel Acquisitions to Add USD 300 million Worth of Assets

PARIS and NEW YORK and LONDON, Dec. 24, 2025 /PRNewswire/ — AMTD Group Inc. (“AMTD Group”), AMTD IDEA Group (NYSE: AMTD; SGX: HKB), AMTD Digital Inc. (NYSE: HKD) and The Generation Essentials Group (“TGE”, NYSE: TGE; LSE: TGE), a subsidiary of AMTD Digital Inc., announce jointly the successful execution of a sales and purchase agreement (“SPA”) for the 100% acquisition of the Hilton Garden Inn New York City Tribeca. Closing of the acquisition is subject to customary closing conditions.

Located at the heart of Tribeca along Avenue of the Americas and bordered by SoHo, Hudson Square, and Battery Park, the Hilton Garden Inn New York City Tribeca is the center of Lower Manhattan’s most dynamic and evolving neighborhoods. The hotel features 151 rooms, more than 5,000 square feet of retail space designated for food and beverage operations, a rooftop area, and amenities including a fitness center and a business center.

Having created the size and magnitude of a fast growing and a globally independent hotel group, TGE celebrates 2025 as a pivotal year for expanding its hospitality business sector, TGE has 4 acquisition deals announced in major cities around the world within the financial year 2025. The successful execution of the SPA of the New York hotel stands out as a significant milestone as TGE closes out the year.

The recent execution of definitive acquisition agreements in relation to three hotels, after TGE’s completion of its de-SPAC transaction with a special purpose acquisition company under Lawrence Ho’s Black Spade Capital, involves a total valuation of over USD300 million of assets and is expected to result in a rapid expansion of TGE’s hotel portfolio by approximately 500 rooms in just 6 months if consummated.

About AMTD Group

AMTD Group is a conglomerate with a core business portfolio spanning across media and entertainment, education and training, and premium assets and hospitality sectors.

About AMTD IDEA Group

AMTD IDEA Group (NYSE: AMTD; SGX: HKB) represents a diversified institution and digital solutions group connecting companies and investors with global markets. Its comprehensive one-stop business services plus digital solutions platform addresses different clients’ diverse and inter-connected business needs and digital requirements across all phases of their life cycles. AMTD IDEA Group is uniquely positioned as an active super connector between clients, business partners, investee companies, and investors, connecting the East and the West. For more information, please visit www.amtdinc.com or follow us on X (formerly known as “Twitter”) at @AMTDGroup.

About AMTD Digital Inc.

AMTD Digital Inc. (NYSE: HKD) is a comprehensive digital solutions platform headquartered in France. Its one-stop digital solutions platform operates key business lines including digital media, content and marketing services, investments as well as hospitality and VIP services. For AMTD Digital’s announcements, please visit https://ir.amtdigital.net/investor-news.

About The Generation Essentials Group

The Generation Essentials Group (NYSE: TGE; LSE: TGE), jointly established by AMTD Group, AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), is headquartered in France and focuses on global strategies and developments in multi-media, entertainment, and cultural affairs worldwide as well as hospitality and VIP services. TGE comprises L’Officiel, The Art Newspaper, movie and entertainment projects. Collectively, TGE is a diversified portfolio of media and entertainment businesses, and a global portfolio of premium properties. Also, TGE is a special purpose acquisition company (SPAC) sponsor manager, with its first SPAC successfully raised and priced on December 18, 2025.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about the beliefs, plans, and expectations of AMTD IDEA Group, AMTD Digital and/or The Generation Essentials Group, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the filings of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group with the SEC. All information provided in this press release is as of the date of this press release, and none of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group undertakes any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

For AMTD IDEA Group:
IR Office
AMTD IDEA Group
EMAIL: ir@amtdinc.com

For AMTD Digital Inc.:
IR Office
AMTD Digital Inc.
EMAIL: ir@amtdigital.net 

For The Generation Essentials Group:
IR Office
The Generation Essentials Group
EMAIL: tge@amtd.world 

GeeLark Introduces a New Era of In-App Social Media Automation

SINGAPORE, Dec. 24, 2025 /PRNewswire/ — For years, social media automation has largely meant one thing: scheduling posts. Conventional social media management tools were built to plan content calendars, publish at optimal times, and track performance through dashboards. However, today’s fastest-growing social networks are mobile-first, algorithm-driven, and heavily influenced by real in-app behavior, which is a reality that traditional desktop-based platforms struggle to address.

GeeLark is changing this landscape by introducing a new generation of mobile social media automation built around cloud phones. Instead of relying on APIs or browser-based workarounds, GeeLark gives marketers access to fully functional Android cloud phones, each operating like a real physical device. This allows users to run social media accounts directly inside mobile apps.

GeeLark goes beyond scheduling by enabling full in-app automation. Through its RPA (Robotic Process Automation) capabilities, GeeLark can automate not only posting, but also liking, commenting, browsing feeds, logging in, and other natural user behaviors within real mobile apps. This makes automation feel less mechanical and more aligned with how actual users interact with social platforms.

GeeLark’s read-to-use RPA automation templates. Users can also create custom flows.
GeeLark’s read-to-use RPA automation templates. Users can also create custom flows.

GeeLark’s automation power is tightly integrated with content creation and account management. The platform connects with advanced AIGC models such as Veo 3, Sora 2, Seedance, and Nano Banana, allowing users to generate, edit, and manage creative assets directly inside GeeLark. Content creation, publishing, and engagement no longer require switching between multiple tools — everything happens in one unified environment.

Once content is ready, GeeLark can distribute it across dozens or hundreds of accounts simultaneously. Whether launching a campaign, testing variations, or scaling engagement, marketers can automate workflows that previously required extensive manual effort or large teams.

Before platforms like GeeLark, scaling mobile automation often meant maintaining physical device farms or relying on unstable emulators. GeeLark replaces these outdated approaches with a cloud-based infrastructure that can be deployed instantly. Cloud phones can be launched in seconds, workflows can be shared across teams, and campaigns can scale without hardware limitations.

This flexibility allows marketers to move faster, test more ideas, and respond to trends in real time, while maintaining operational stability and security.

For years, social media automation has largely revolved around scheduling posts and tracking analytics, but as platforms evolve, this approach is no longer enough. Today’s fastest-growing social networks are mobile-first, algorithm-driven, and heavily influenced by real in-app behavior — a reality that traditional desktop-based tools struggle to address. GeeLark is changing this landscape by introducing a new generation of mobile social media automation built around cloud phones.

As a cloud-phone platform, GeeLark provides users with fully functional Android devices hosted in the cloud, allowing marketers to operate social media accounts directly inside native mobile apps rather than through limited APIs or browser tools. This enables a deeper level of automation that goes far beyond publishing posts, including automated liking, commenting, browsing, logging in, and other natural user behaviors that social algorithms prioritize.

By automating real in-app actions, GeeLark allows brands, creators, and agencies to scale engagement in a way that feels authentic and aligns with how platforms like TikTok, Instagram Reels, YouTube Shorts, WhatsApp, and Telegram are designed to work.

GeeLark also functions as an end-to-end automation engine by combining content creation, distribution, and engagement within a single platform. With integrations to advanced AIGC models such as Veo3, Seedance, and Nano Banana, users can generate, edit, and manage creative content directly inside GeeLark without switching tools.

Once content is ready, GeeLark’s RPA automation can distribute it across dozens or even hundreds of accounts simultaneously, enabling large-scale campaigns, rapid testing, and efficient growth. Each cloud phone operates in an isolated environment with its own device fingerprint and configurable proxy, allowing safe multi-account management, regional testing, and global campaign execution without accounts being linked or restricted.

Unlike traditional approaches that rely on physical device farms or unstable emulators, GeeLark’s cloud-based infrastructure allows new devices and workflows to be deployed instantly, shared across teams, and scaled without hardware limitations.

As social media continues to shift toward mobile-native experiences and behavior-driven algorithms, GeeLark represents a fundamental change in how automation is defined. By moving beyond scheduling and enabling real mobile automation at scale, GeeLark is ushering in a new era of social media marketing — one built for the realities of today’s platforms and the opportunities of tomorrow.

Contact:
Name: Eleanor Tse
Email: eleanor.tse@geelark.com 

FP Markets Celebrates 20 Years of Transforming Trading and Looks Ahead to a New Era of Growth

SYDNEY, Dec. 24, 2025 /PRNewswire/ — Global multi-asset broker FP Markets proudly marked its twentieth anniversary this year, celebrating two decades of ‘Transforming Trading’ through innovation, performance-driven technology, and a commitment to placing traders first.

Since its founding in 2005, FP Markets has consistently redefined trading excellence, developing next-generation financial technology, delivering comprehensive trader education, and providing exceptional customer support tailored to a diverse client base.

 

FP Markets Celebrates 20 Years of Transforming Trading and Looks Ahead to a New Era of Growth
FP Markets Celebrates 20 Years of Transforming Trading and Looks Ahead to a New Era of Growth

 

In 2025, the broker further solidified its industry-leading position with continued global expansion, a refreshed digital brand identity, multiple product enhancements, and participation in major financial international expos. The past year was also marked with significant achievements as FP Markets received over 20 international acknowledgements, including ‘Broker of the Year – Global’, ‘Most Valuable Broker’, and ‘Most Reputable Broker’.

Commenting on the company’s milestone anniversary, Andria Phiniefs, Global Head of Marketing, stated: “FP Markets pledges to continue pushing boundaries and setting new industry standards, expanding access to markets worldwide while remaining firmly grounded in our values. With innovation and our client-centric focus at the core of everything we do, we are well positioned and ready for our next era of growth.”

Looking ahead, FP Markets will be continuing its strategic expansion into new regions and emerging markets with the aim of delivering trading solutions to a broader global audience. The broker also plans to expand its financial technology, tools, and product suite to meet the evolving needs of traders. While fully embracing technological progress, FP Markets remains firmly committed to its customer-centric philosophy, ensuring fintech innovation is complemented by exemplary education and unmatched client support.